Engineered immune cells take on lupus in early trial
NCT ID NCT06222853
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a new treatment for people with refractory systemic lupus erythematosus, a severe form of lupus that doesn't improve with standard medicines. The treatment uses the patient's own immune cells, modified to target and attack faulty immune cells that drive the disease. The main goal is to check safety, but researchers will also look for signs that the treatment can reduce lupus activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-CD19 CAR-T cells
What this could lead to
If successful, this could point toward a new treatment option for people with severe lupus that hasn't responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 22 participants, so results may not apply broadly. CAR-T therapy carries risks like cytokine release syndrome and neurotoxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China